Viatris Q2 profit beats on growth in new product sales

Viatris

06/08/2026 12:09

Overview
Healthcare company's Q2 revenue rose 5%, beating analyst expectations
Adjusted EPS for Q2 up 11%, beating analyst expectations
Company returned about $550 mln to shareholders, including share repurchases

Outlook
Viatris raises 2026 revenue guidance to $14.55 bln-$14.95 bln
Company expects 2026 adjusted EPS of $2.45-$2.59
Viatris anticipates $100 mln-$150 mln revenue impact from Nashik supply disruptions in H2 2026

Result Drivers
NEW PRODUCT SALES - Co said Q2 revenue growth was primarily driven by new product sales in Developed Markets and strong growth in Greater China
GENERIC AND BRAND PERFORMANCE - Brands net sales reflected continued strength in Greater China and Emerging Markets, while generics net sales benefited from new launches and growth in Developed Markets, partly offset by supply constraints in the ARV business within Emerging Markets
NON-CASH CHARGE - Q2 net loss was primarily driven by a non-cash charge related to the planned sale of Tyrvaya product rights and the write down of that intangible asset

Company press release: ID:nPn2Yvj31a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.76 bln
$3.68 bln (6 Analysts)
Q2 Adjusted EPS
Beat
$0.69
$0.60 (7 Analysts)
Q2 Loss Per Share
 
$0.10
 
Q2 Net Loss
 
$118.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Viatris Inc. is $18.00, about 2% above its August 5 closing price of $17.65
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 6 three months ago

Reuters Recommended Reads
Aug 6 - UK's Hikma Pharma holds annual outlook, prepares for US generic drug tariffs
Aug 5 - India's Aurobindo Pharma posts quarterly profit rise on anti-retroviral drug demand
Aug 5 - Sandoz gains on strong biosimilar growth, touts 'golden decade'

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)